comprehensive -WSS

comprehensive

author：focus 2025-09-30 18:20:42 - browse：85

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Boston hospital trains restaurant workers on naloxone for overdoses

WSS

WuXi Biologics execs register to lobby as Congress comes for the company

Impact of Dobbs ruling felt at reproductive medicine meeting

Supreme Court to hear if Covid misinformation is protected speech

Cherokee Nation medical school graduates its first class

Solve the antibiotic resistance crisis with preventive drugs

The White House hikes tariffs on plastic syringes made in China

hotspot

comprehensive

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Fertility clinic egg and embryo storage is a disaster

Wildfire smoke exposes gaps in outdoor worker protections

Free medical tuition alone isn't enough to close gaps in primary care

New air purifier tech could be key to improving indoor air quality

Novo Nordisk testing Wegovy against alcohol

Drug repurposing or repositioning? The language matters

Hottest summer in 2,000 years puts focus on extreme heat, health

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

knowledge

ALS treatment from Biogen, Ionis fails in study

Hottest summer in 2,000 years puts focus on extreme heat, health

STAT Summit: How a Chicago ER doctor tackles gun violence

Senate committee scrutinizes Medicare Advantage brokers

HHS suspends federal funding for EcoHealth Alliance

STAT Summit: GSK CEO on pharma giant's new direction

focus

hotspot

entertainment

focus